Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients

被引:14
|
作者
Saleki, Kiarash [1 ,2 ,3 ,4 ]
Shirzad, Moein [1 ,2 ,4 ]
Javanian, Mostafa [5 ]
Mohammadkhani, Sheyda [2 ]
Alijani, Mohammad Hossein [2 ]
Miri, Niloufarsadat [1 ]
Oladnabi, Morteza [6 ]
Azadmehr, Abbas [1 ,4 ,7 ]
机构
[1] Babol Univ Med Sci, Hlth Res Inst, Cellular & Mol Biol Res Ctr, Babol, Iran
[2] Babol Univ Med Sci, Student Res Comm, Babol, Iran
[3] Babol Univ Med Sci, USERN Off, Babol, Iran
[4] Natl Elite Fdn, Mazandaran Prov Branch, Mazandaran, Iran
[5] Babol Univ Med Sci, Hlth Res Inst, Infect Dis & Trop Med Res Ctr, Babol, Iran
[6] Golestan Univ Med Sci, Ischem Disorders Res Ctr, Gorgan, Iran
[7] Babol Univ Med Sci, Immunol Dept, Babol, Iran
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
COVID-19; hyperinflammation; Fas; viral Immunology; immunoinformatics; AA FORCE-FIELD; EXPRESSION; APOPTOSIS; INJURY; ACTIVATION; VIRUS; GENE;
D O I
10.3389/fimmu.2022.947401
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Finding cytokine storm initiator factors associated with uncontrolled inflammatory immune response is necessary in COVID-19 patients. The aim was the identification of Fas/Fas Ligand (FasL) role in lung involvement and mortality of COVID-19 patients. In this case-control study, mild (outpatient), moderate (hospitalized), and severe (ICU) COVID-19 patients and healthy subjects were investigated. RNA isolated from PBMCs for cDNA synthesis and expression of mFas/mFasL mRNA was evaluated by RT-PCR. Serum sFas/sFasL protein by ELISA and severity of lung involvement by CT-scan were evaluated. Also, we docked Fas and FasL via Bioinformatics software (in silico) to predict the best-fit Fas/FasL complex and performed molecular dynamics simulation (MDS) in hyponatremia and fever (COVID-19 patients), and healthy conditions. mFasL expression was increased in moderate and severe COVID-19 patients compared to the control group. Moreover, mFas expression showed an inverse correlation with myalgia symptom in COVID-19 patients. Elevation of sFasL protein in serum was associated with reduced lung injury and mortality. Bioinformatics analysis confirmed that blood profile alterations of COVID-19 patients, such as fever and hyponatremia could affect Fas/FasL complex interactions. Our translational findings showed that decreased sFasL is associated with lung involvement; severity and mortality in COVID-19 patients. We think that sFasL is a mediator of neutrophilia and lymphopenia in COVID-19. However, additional investigation is suggested. This is the first report describing that the serum sFasL protein is a severity and mortality prognostic marker for the clinical management of COVID-19 patients.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Serum levels of soluble Fas and soluble Fas ligand in patients with primary biliary cirrhosis.
    Deguchi, A
    Arima, K
    Nishioka, M
    HEPATOLOGY, 1999, 30 (04) : 566A - 566A
  • [32] Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker in COVID-19 patients: a systematic review
    Lobato-martinez, E.
    Sanchez-martinez, R.
    Balsa, E. de-miguel
    Ramos-rincon, J. -m.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2024, 28 (02) : 852 - 860
  • [33] Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19
    Ren, Huihui
    Yang, Yan
    Wang, Fen
    Yan, Yongli
    Shi, Xiaoli
    Dong, Kun
    Yu, Xuefeng
    Zhang, Shujun
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [34] SPONTANEOUS PNEUMOMEDIASTINUM: PROGNOSTIC MARKER IN PATIENTS WITH COVID-19 PNEUMONIA?
    Patel, Femina
    Ghosh, Sudeshna
    Ansari, Saad
    Chitkara, Akshit
    CHEST, 2022, 162 (04) : 2478A - 2478A
  • [35] Serum Cystatin C Levels as a Predictor of Severity and Mortality Among Patients With COVID-19 Infection
    Prasad, Kavya
    Kulkarni, Ashwin
    Navikala, K.
    Gowda, Vanitha
    Shaikh, Mohammed Aslam
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
  • [36] Memory B cells and serum immunoglobulins are associated with disease severity and mortality in patients with COVID-19
    Colkesen, Fatih
    Kepenek Kurt, Esma
    Vatansev, Hulya
    Korkmaz, Celalettin
    Colkesen, Fatma
    Yucel, Fatih
    Yildiz, Eray
    Evcen, Recep
    Aykan, Filiz Sadi
    Kilinc, Mehmet
    Aytekin, Gokhan
    Feyzioglu, Bahadir
    Dogan, Metin
    Arslan, Sevket
    Teke, Turgut
    Keles, Sevgi
    Reisli, Ismail
    POSTGRADUATE MEDICAL JOURNAL, 2022, 98 (1164) : 765 - 771
  • [37] Serum biomarkers for prediction of mortality in patients with COVID-19
    Loomba, Rohit S.
    Villarreal, Enrique G.
    Farias, Juan S.
    Aggarwal, Gaurav
    Aggarwal, Saurabh
    Flores, Saul
    ANNALS OF CLINICAL BIOCHEMISTRY, 2022, 59 (01) : 15 - 22
  • [38] Serum levels of soluble Fas ligand and Fas in patients with acute and fulminant hepatitis
    Suzuki, K
    Takikawa, Y
    Iwai, M
    Endo, R
    Abe, K
    Nakadate, I
    Kato, A
    Sato, S
    Yatomi, T
    Nakamura, N
    HEPATOLOGY, 1997, 26 (04) : 1921 - 1921
  • [39] COVID-19 Mortality and Severity in Cancer Patients and Cancer Survivors
    Park, Jae -Min
    Koo, Hye Yeon
    Lee, Jae-ryun
    Lee, Hyejin
    Lee, Jin Yong
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (02)
  • [40] Gender Differences in Patients With COVID-19: Focus on Severity and Mortality
    Jin, Jian-Min
    Bai, Peng
    He, Wei
    Wu, Fei
    Liu, Xiao-Fang
    Han, De-Min
    Liu, Shi
    Yang, Jin-Kui
    FRONTIERS IN PUBLIC HEALTH, 2020, 8